Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective imatinib (Gleevec) is in treating
acral/lentiginous and mucosal melanoma which has spread to other parts of the body in
patients who's disease carries a c-kit mutation. Imatinib is a protein-kinase inhibitor. It
is believed that imatinib may be effective in blocking signals on certain cancer cells which
allow the malignant cells to multiply and spread.